• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Holistic Fertility Management and Payer Collaboration

Opinion
Video

An expert spotlights how open data communication between payers and fertility clinics can drive collaboration expanding coverage for proven, successful treatments that crucially improve assisted reproductive outcomes when timely access barriers are eliminated through aligned medical policies.

This is a video synopsis/summary of a Population Health Perspectives® involving Sean Tipton.In the video, Tipton, of the American Society for Reproductive Medicine (ASRM), discusses the role of payers in American healthcare, specifically in providing quality control and ensuring providers deliver good care. He notes that in vitro fertilization clinics have good outcomes data available through required federal reporting and ASRM’s affiliate, the Society for Assisted Reproductive Technology. However, he cautions that clinic success rates must be carefully interpreted as they do not account for patient difficulty. Tipton advises that payers work with clinics to reward effective practices and limit unsuccessful treatments. He advocates for reproductive medicine to receive the same coverage as other medical care, arguing that comprehensive fertility benefits do not substantially raise costs for employers and payers. Additionally, lack of coverage can lead to inappropriate care and consequences that increase spending. Tipton calls for an “enlightened partnership” between payers and providers focused on efficient, quality care to help more patients. He acknowledges the inherent tensions between payers and providers due to differing goals and incentives, but stresses the importance of prioritizing optimal, cost-effective care. Open communication and mutual understanding are key. Providers must better comprehend performance outcomes and be willing to discuss cost-efficiency, whereaspayers cannot ignore costs. Ultimately, honest dialogue will benefit patients.

Video synopsis is AIgenerated and reviewed by Managed Healthcare Executive® editorial staff. 

Related Videos
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
Video 6 - "Failing to Reach Ideal Diabetes Care: Equitable Doesn’t Mean Equal"
Video 5 - "Revising Diabetes Outcome Measures"
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
© 2024 MJH Life Sciences

All rights reserved.